On Friday, Baird reaffirmed its Outperform rating on shares of Longboard Pharmaceuticals Inc (NASDAQ:LBPH) with a price target of $60.00. The firm expressed a positive outlook on the company following recent meetings with Longboard's management. The discussions bolstered Baird's opinion that Longboard Pharmaceuticals is significantly undervalued in comparison to other companies in its sector.
The analyst at Baird highlighted the anticipation for Longboard's upcoming investor and analyst event scheduled for September 16. This event is expected to provide further information on Longboard's global phase 3 program. The program's focus is on bexicaserin, a treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs), intended for use in individuals aged two years and older.
Bexicaserin is poised to enter a pivotal stage with the global phase 3 program, which could potentially address the needs of patients suffering from DEEs, a group of conditions that are often resistant to treatment and have a significant impact on quality of life.
As of now, Longboard Pharmaceuticals is preparing to share more details about its plans and the progress of its clinical program. The investor and analyst community is awaiting the September 16 event to gain insights into the potential impact of bexicaserin on Longboard's growth and its position in the pharmaceutical industry.
The reiterated price target and rating reflect Baird's confidence in Longboard Pharmaceuticals' prospects and its ongoing commitment to developing treatments for complex neurological conditions. The market will be watching closely for updates from the company's event in mid-September.
In other recent news, Longboard Pharmaceuticals has seen a series of positive developments. The company's drug, bexicaserin, received Breakthrough Therapy designation from the FDA for treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in patients aged two years and older. This significant regulatory development led Baird to raise its price target for Longboard from $36 to $60, while maintaining an Outperform rating.
Citi also increased its price target from $40 to $45, maintaining a Buy rating, following the FDA's approval of a Phase 3 study for bexicaserin. The study targets different patient subsets, including Dravet syndrome and Lennox-Gastaut syndrome. Further, Longboard reported promising initial results from the PACIFIC OLE study, indicating a reduction in seizure frequency.
Other analysts, including those from H.C. Wainwright & Co and Cantor Fitzgerald, also hold a bullish stance, setting a price target of $60. This shows the confidence in Longboard's growth prospects following the FDA's recognition of bexicaserin's potential in treating DEEs.
Longboard plans to initiate a Phase 3 program by the end of 2024 and expects Phase 1 data for another therapeutic candidate, LP659, in the second quarter of 2024. These recent developments highlight Longboard's potential to address significant unmet needs in epilepsy treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.